Asb10通过稳定HSP70来加速病态心脏重塑
Ke Lin1,2,3, Wenjie Wei2,4, Songzan Chen1,2,3
1Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Cell death & disease
|May 21, 2025
概括
Asb10通过稳定HSP70,这是心力衰竭发展的关键因素,从而加剧心脏缩. 抑制Asb10可能为压力过载引起的心脏病提供治疗策略.
科学领域:
- 心血管生物学 心血管生物学
- 分子心脏病学分子心脏病学
- 心脏衰竭的发病因子 发病因子
背景情况:
- 心脏缩是心力衰竭的主要危险因素.
- 高血压引起的压力过载是左心室缩的常见触发因素.
- 人们越来越多地认识到,在心脏缩中,无素-蛋白酶体系统的作用.
研究的目的:
- 调查心脏组织丰富的E3酶Asb10在心脏缩和心脏衰竭中的作用.
- 阐明Asb10影响心脏缩的分子机制.
主要方法:
- 对GEO数据集的生物信息选和实验验证.
- 在实验室中使用NRVMs与腺病毒Asb10过度表达的研究.
- 免疫沉质谱和共免疫沉试验.
- 在小鼠体内进行的体内研究,小鼠接受过横向大动脉收缩 (TAC) 手术.
主要成果:
- Asb10在心脏缩中被确定为下调.
- Asb10的过度表达加剧了TAC后的缩生长和恶化的心脏功能.
- Asb10通过阻断STUB1介导的泛化和降解来稳定HSP70.
- 升高的HSP70,心脏炎症和pHDAC2S394激活与Asb10的影响有关.
结论:
- 通过竞争性抑制STUB1.1,Asb10通过稳定HSP70来加剧心脏缩.
- Asb10在血液动力学压力诱导的心脏缩和心力衰竭中发挥着重要作用.
- 准Asb10或HSP70可能代表心力衰竭的治疗方法.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
356
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K